BI 894999 First in Human Dose Finding Study in Advanced Malignancies
- Conditions
- NeoplasmsNUT Carcinoma
- Interventions
- Drug: BI 894999
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 174
- Registration Number
- NCT02516553
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02516098
- Locations
- 🇨🇦
Boehringer Ingelheim Investigational Site, Bloemfontein, Canada
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02514174
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Baystate Health D'Amour Center for Cancer Care, Springfield, Massachusetts, United States
🇺🇸Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States
Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- Drug: BI 836909
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 43
- Registration Number
- NCT02514239
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Germany
🇫🇷HOP Hôtel-Dieu, Nantes, France
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02513446
- Locations
- 🇩🇪
1320.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 880
- Registration Number
- NCT02489968
- Locations
- 🇯🇵
Ebetsu Internal Medicine Clinic, Hokkaido, Ebetsu, Japan
🇯🇵Iida Medical Clinic, Hokkaido, Hakodate, Japan
🇯🇵Morinagaueno clinic, Kumamoto, Digestive Tract I.M., Kumamoto, Kumamoto, Japan
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 359
- Registration Number
- NCT02489981
- Locations
- 🇧🇷
Hospital Felício Rocho, Belo Horizonte, Brazil
Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8145
- Registration Number
- NCT02489942
Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02483416
- Locations
- 🇫🇷
HOP CHD La Roche sur Yon - Montaigu - Luçon, Pneumo, La Roche Sur Yon cedex, France
🇫🇷CHR d'Annecy, Oncologie, Annecy, Pringy, France
🇫🇷CLI Dr Calabet, Oncolgie, Agen, Agen, France
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 275
- Registration Number
- NCT02453555
- Locations
- 🇯🇵
Fukuwa Clinic, Tokyo, Chuo-ku, Japan
🇯🇵Nakakinen Clinic, Ibaraki, Naka, Japan
🇯🇵Hiraoka Naika Clinic, Hiroshima, I.M., Hiroshima, Hiroshima, Japan